Filing Flows › Relay Therapeutics (RLAY) › Q1 2026
Relay Therapeutics (RLAY) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Relay Therapeutics (RLAY) reported revenue of $3.0M for the first quarter 2026 (Q1 2026), -61% from a year earlier and -57% from the quarter before.
Relay Therapeutics, Q1 2026: revenue $3.0M (-61% year over year), net loss $73.3M, operating cash flow −$51.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.0M | -57% | -61% |
| Operating profit | −$78.6M | — | — |
| Net earnings | −$73.3M | — | — |
| Operating cash flow | −$51.1M | — | — |
What changed
Revenue was $3.0M in Q1 2026, down 61% year over year and down 57% from the previous quarter.
Operating costs exceeded revenue by $78.6M, an operating margin of -2619.7%. Total costs fell 12% while revenue fell 61%. The quarter ended with a net loss of $73.3M, wider than the previous quarter's $54.9M loss.
Operating cash flow was −$51.1M. Non-cash charges added back $504K of depreciation and $10.5M of share-based compensation. Working capital and other items added $11.1M.
Questions
What was Relay Therapeutics' revenue in the first quarter 2026?
Relay Therapeutics (RLAY) reported revenue of $3.0M for the first quarter 2026 (Q1 2026), -61% from a year earlier and -57% from the quarter before.
Source: Relay Therapeutics 10-Q on SEC EDGAR.